Summary
Quest Diagnostics reported a strong first quarter of 2021, with net revenues significantly increasing by 49.3% year-over-year to $2.72 billion. This growth was primarily driven by a substantial increase in demand for COVID-19 testing, which boosted both volume and revenue per requisition. Despite the decline in COVID-19 testing demand in the latter part of the quarter, the company saw a recovery in its base business volumes compared to the prior year, though still below pre-pandemic 2019 levels. The company generated substantial operating income and net income, with diluted earnings per share reaching $3.46, a significant improvement from $0.73 in the prior year period. Operationally, Quest Diagnostics demonstrated robust cash flow from operations, increasing by over threefold to $731 million, providing ample resources for investing activities and financing. The company also continued its commitment to returning capital to shareholders through dividends and a substantial share repurchase program, which was further increased during the quarter. Looking ahead, Quest Diagnostics announced an agreement to acquire Mercy Health's outreach laboratory services business and the subsequent sale of its stake in Q2 Solutions, which is expected to result in a significant pre-tax gain. The company is also advancing its cost-reduction and performance improvement program, Invigorate.
Financial Highlights
56 data points| Revenue | $2.72B |
| Cost of Revenue | $1.63B |
| Gross Profit | $1.09B |
| SG&A Expenses | $407.00M |
| Operating Expenses | $2.06B |
| Operating Income | $660.00M |
| Interest Expense | $38.00M |
| Net Income | $469.00M |
| EPS (Basic) | $3.52 |
| EPS (Diluted) | $3.46 |
| Shares Outstanding (Basic) | 133.00M |
| Shares Outstanding (Diluted) | 135.00M |
Key Highlights
- 1Net revenues surged 49.3% year-over-year to $2.72 billion, largely due to strong COVID-19 testing demand.
- 2Diluted earnings per share (EPS) rose significantly to $3.46 from $0.73 in the prior year quarter, reflecting improved profitability.
- 3Net cash provided by operating activities increased dramatically to $731 million, up from $247 million in Q1 2020, indicating strong cash generation.
- 4The company continued its capital return program with increased share repurchases and a declared quarterly dividend.
- 5Quest Diagnostics is expanding its operations through the announced acquisition of Mercy Health's outreach laboratory services business.
- 6The sale of the company's stake in Q2 Solutions for $760 million is expected to generate a significant pre-tax gain in Q2 2021.
- 7Base business testing volumes showed recovery year-over-year but remain below 2019 levels, indicating continued focus on post-pandemic normalization.